Report Overview

The UK Guillain-Barre Syndrome (GBS) therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Guillain-Barre Syndrome is a rare condition concerning the immune system of the body. In Guillain-Barre Syndrome, the bodys immune system starts attacking the bodys own nervous system, resulting in pain and loss of sensation, as well as weakness and pins and needles feeling in the limbs. However, the disease has often been seen to be accompanied by respiratory infections and the stomach flu. Other names for Guillain-Barre syndrome include acute idiopathic polyneuritis, acute idiopathic polyradiculoneuritis, and Landrys ascending paralysis.

Guillain-Barre Syndrome is rare, affecting one out of every 100,000 people irrespective of gender or age, although it is more common in the 30 to 50 years age group according to a report. Mayo Clinic Healthcare UK specialists have extensive experience with GBS syndrome, treating more than 380 people with Guillain-Barre Syndrome every year. Around nine out of 10 people with Guillain-Barre Syndrome survive and approximately 75 to 90 percent recover completely, while around 10 to 15 percent will be troubled by some form of permanent disability in the future.



Market Growth Drivers

An increasing number of patients with GBS, family history of GBS, strong product pipeline, and increasing financial support to researchers for developing new innovative drugs for the treatment of GBS are likely to drive the GBS market during the forecast period.

Growing awareness about Guillain-Barr syndrome is likely to be a major driver for the Guillain-Barre syndrome market in the UK. The increasing investment into research and development from pharmaceutical companies in the field of discovering cures for rare diseases are likely to be a stimulant for the Guillain-Barre syndrome market over the forecast period

In addition, an increase in special designation from the regulatory authorities to offer treatment to the patients as quickly as possible is enhancing the market. The growing geriatric population is also likely to be a major driver for the Guillain-Barr syndrome market over the forecast period. Immune system disorders are often seen more commonly in the elderly than in younger demographics.